Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 90Active not recruiting 55Completed 19Not yet recruiting 14Terminated 9Withdrawn 3Enrolling by invitation 2Available 2Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 10Breast Neoplasms 10Neoplasms 9Leukemia, Myeloid, Acute 9Neoplasm Metastasis 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Pancreatic Neoplasms 5Myelodysplastic Syndromes 5Lung Neoplasms 5Hematologic Neoplasms 5Ovarian Neoplasms 4Multiple Myeloma 4Glioma 4Uterine Cervical Neoplasms 3Sarcoma 3Melanoma 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Astrocytoma 3Triple Negative Breast Neoplasms 2Solid Tumors 2Solid Tumor 2Recurrence 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2

Interventions

olaparib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Urinary Bladder Neoplasms × 90 days × Clear all
NCT03375307 2026-06-05

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

National Cancer Institute (NCI)

Phase 2 Suspended
60 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡